Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB018A Injection in Thyroid Eye Disease Extension Study
CTR20254672Phase 3Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Dec 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of MHB018A in Graves Orbitopathy (GO), sponsored by Minghui Pharmaceutical, Inc. Primary endpoint: Proptosis response rate at week 24. Started Dec 2025; status: active.
02
Drugs
MHB018A
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20254672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254672.